Abstract: Disclosed is a method for assistance with the establishment of a diagnosis of a patient, starting from at least one identified sign, and based on a computerized knowledge database including a medical ontology. The medical ontology includes: a list of signs forming a “sign” class; a list of pathological states forming a “pathological state” class; and a first set of logical relationships between the signs and the pathological states, each logical relationship establishing a correlative link between a sign and a pathological state. The method includes: a step of searching for potential pathological states, linked to at least one of the identified signs by the first set of logical relationships; and a step of identifying potential signs in which, for each potential pathological state, all of the signs linked by a correlative link to the potential pathological state are identified by the first set of logical relationships.

Abstract: Method and system for evaluating arterial pressure waves, vascular properties, as well as for diagnostic, physiological and pharmacological testing using various combinations of the following data acquisition and processing steps (some of the steps are optional): 1. Perturbing arterial pressure from its steady state. 2. Measuring the dynamics of at least one parameter related to the passage of arterial pressure waves along blood vessels. 3. Characterizing the magnitude and functional relation of changes in parameters described above in relation to changes in blood pressure during its displacement from and/or return to the steady state. 4. Classifying (comparing) the individual functional relation described above with a databank of parameters/functional relations for different states of vasomotor activity.

Abstract: A system, method and apparatus for executing a bioinformatics analysis on genetic sequence data is provided. Particularly, a genomics analysis platform for executing a sequence analysis pipeline is provided. The genomics analysis platform includes one or more of a first integrated circuit, where each first integrated circuit forms a central processing unit (CPU) that is responsive to one or more software algorithms that are configured to instruct the CPU to perform a first set of genomic processing steps of the sequence analysis pipeline.

Abstract: Methods are provided for predicting a subject's infection status using high-throughput T cell receptor sequencing to match the subject's TCR repertoire to a known set of disease-associated T cell receptor sequences. The methods of the present invention may be used to predict the status of several infectious agents in a single sample from a subject. Methods are also provided for predicting a subject's HLA status using high-throughput immune receptor sequencing.

Abstract: A system, method and apparatus for executing a sequence analysis pipeline on genetic sequence data includes an integrated circuit formed of a set of hardwired digital logic circuits that are interconnected by physical electrical interconnects. One of the physical electrical interconnects forms an input to the integrated circuit connected with an electronic data source for receiving reads of genomic data. The hardwired digital logic circuits are arranged as a set of processing engines, each processing engine being formed of a subset of the hardwired digital logic circuits to perform one or more steps in the sequence analysis pipeline on the reads of genomic data. Each subset of the hardwired digital logic circuits is formed in a wired configuration to perform the one or more steps in the sequence analysis pipeline.

Abstract: A device obtains a series of measurements of a physiological parameter of one or more patients. The device displays a monitoring workflow home screen when the device is operating within a monitoring workflow. The device displays a non-monitoring workflow home screen when the device is operating within a non-monitoring workflow. The device displays a continuous workflow home screen when the device is operating within a continuous workflow. The monitoring workflow home screen, the non-monitoring workflow home screen, and the continuous workflow home screen are each different.

Abstract: Methods are provided for identifying T cell receptors that specifically bind a particular antigenic target and can be used as therapeutics against disease.

Abstract: Provided are methods and apparatus for receiving sensor data from an analyte sensor of a sensor monitoring system, processing the received sensor data with time corresponding calibration data, outputting the processed sensor data, detecting one or more adverse conditions associated with the sensor monitoring system, disabling the output of the sensor data during the adverse condition time period, determining that the one or more detected adverse conditions is no longer present in the sensor monitoring system, retrieving the sensor data during the adverse condition time period, processing the retrieved sensor data during the adverse condition time period, and outputting the processed retrieved sensor data.

Abstract: A computer-implemented system for determining a genomic testing status of a patient may include at least one processor programmed receive, from a source, unstructured information from a plurality of patient records associated with a patient; determine, using a first machine learning model, a primary patient record from among the plurality of patient records, wherein at least a portion of information represented in the primary patient record correlates to genomic testing; determine, using a second machine learning model and based on unstructured information from one at least one of the patient records, a likelihood of an occurrence of genomic testing for the patient; determine a genomic testing status of the patient based on the determined likelihood of the occurrence of genomic testing; and display a user interface comprising an indicator of the genomic testing status of the patient and a link to the primary patient record.

Abstract: A sequencing data analysis method, a device and a computer-readable medium for microsatellite instability. The present invention can use NGS sequencing results to determine whether the microsatellite instability is present. The sequencing data analysis method can significantly improve detection sensitivity without reducing specificity, and can quickly and automatically evaluate a stable or unstable status of each MSI locus with high throughput, high sensitivity, and high specificity. By combining the statuses for all MSI loci in each sample, the samples can be comprehensively evaluated as MSS, MSI-L, or MSI-H.

Abstract: Provided here are systems and methods for predicting risk of a substance use disorder and for providing decision support to healthcare professionals to implement a treatment regimen recommendation and mitigate any potential risk of a substance use disorder.

Abstract: Embodiments of the disclosure relate to a screening method for the diagnosis of haematological neoplasia. In the method, a first test step is performed to check whether a potential haematological neoplasia exists. At least a first haematogram is created with a blood sample in the first test step. Based on a first set of filter rules, it is checked whether the first haematogram differs from a desired state specified according to the first set of filter rules, and a second test step is performed to check for potential haematological neoplasia if the first test step reveals that there is potential haematological neoplasia. In addition, the disclosure relates to a system, a computer program product, and a computer-readable storage medium.

Abstract: Methods and apparatus to identify and quantify the microorganisms present in a sample. Sequence reads are classified using existing methods, but the classification results are corrected to account for the number of reads expected to be falsely classified as determined through simulation. With statistics on the expected number of reads misclassified, a linear least squares method (non-negative or otherwise) or other related technique can be used to adjust the number of reads that are classified to various taxonomic units (e.g., species) and to determine more accurate values for the quantities of those taxonomic units actually present in the sample, eliminating microorganisms in taxonomic units falsely determined to be present in the sample.

Abstract: The present invention provides methods and materials useful for determining metabolizer status. Embodiments of the present invention provide an approach using a genotyping panel and integration of genotypes of CYP3A4 and CYP3A5 to assess CYP3A metabolizer status, applicable to all CYP3A substrates, including approximately 40% of all drugs. Algorithms for CYP3A metabolizer status are described. Where the contribution ratios of CYP3A4 and CYP3A5 to overall drug levels or drug effects are known, the algorithm can be used to calculate optimal dosing. Where the contributory ratios to overall drug effects are not available, the contributory ratios can be calculated with use of the genotypes for use in drug development. Embodiments of the present invention can be used in optimizing drug treatments, selecting dose, designing therapeutics, and predicting efficacy.

Abstract: Methods, systems, and software are provided for determining a homologous recombination pathway status of a cancer in a test subject, e.g., to improve cancer treatment predictions and outcomes. In some embodiments, classifiers using one or more of (i) a heterozygosity status for DNA damage repair genes in a cancerous tissue, (ii) a measure of the loss of heterozygosity across the genome of the cancerous tissue, (iii) a measure of variant alleles detected in a second plurality of DNA damage repair genes in the genome of the cancerous tissue, (iv) a measure of variant alleles detected in the second plurality of DNA damage repair genes in the genome of a non-cancerous tissue, and (v) tumor sample purity are provided.

Abstract: Provided are methods and apparatus for receiving sensor data from an analyte sensor of a sensor monitoring system, processing the received sensor data with time corresponding calibration data, outputting the processed sensor data, detecting one or more adverse conditions associated with the sensor monitoring system, disabling the output of the sensor data during the adverse condition time period, determining that the one or more detected adverse conditions is no longer present in the sensor monitoring system, retrieving the sensor data during the adverse condition time period, processing the retrieved sensor data during the adverse condition time period, and outputting the processed retrieved sensor data.

Abstract: A system and method for evaluating effects of an antiarrhythmic agent. The system includes: an action potential measurement unit for measuring a cardiac action potential of a patient; an ion channel characteristics determination unit for determining ion channel characteristics of the patient using the cardiac action potential; and an antiarrhythmic agent effect evaluation unit for simulating a treatment effect of an antiarrhythmic agent by reflecting characteristics of the antiarrhythmic agent on the determined ion channel characteristics of the patient. The system can conveniently determine the patient's ion channel characteristics by measuring the cardiac action potential of the patient, thereby preventing the risk of gathering cardiomyocytes of the patient.

Abstract: The invention relates to the use of novel biomarkers and biomarker combinations having utility in the early determination of an individual's critical and/or life threatening response to illness and/or in predicting outcome of said illness. The measurement of expression levels of the products of the biomarkers and combinations of biomarkers of the invention have utility in making the determination of an individual's critical and/or life threatening response to illness. In some embodiments, the biomarker and biomarker combinations are agnostic and are independent of the pre-identification and/or determination of the cause or nature of the illness. In some embodiments, the biomarkers and biomarker combinations can be utilized to select treatment and/or monitor the effectiveness of treatment interventions for an individual who has a critical illness.

Abstract: The present invention provides for a method to identify a hospital acquired infection. The method includes computing the number of changes over time between an infection sample and at least a subset of the plurality of infection samples and determining if the number of changes over time is within an interval of an expected number of changes. If so, marking the infection sample as a hospital acquired infection.

Abstract: The clinical course of idiopathic pulmonary fibrosis (IPF) is difficult to predict. Described herein is a peripheral blood 52-gene expression signature useful to improve outcome prediction in IPF.